USPTO Letter to FDA CDER Regarding Patent Procedures

The USPTO sent a letter to FDA CDER addressing patent procedures between the two agencies. The document was filed in the regulatory docket system on April 9, 2026. As inter-agency correspondence, this filing does not impose new regulatory requirements on external parties.

Affected parties should monitor the docket for any FDA responses or related filings that may indicate shifts in patent examination procedures or drug approval processes involving patent matters.